Epidermolysis bullosa and cancer

Clinical and Experimental Dermatology

Volumn 27, Issue 8, 2002, Pages 616-623

  Mallipeddi, Raj ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; METHOTREXATE;

BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; DISEASE ASSOCIATION; EPIDERMOLYSIS BULLOSA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MELANOMA; PANCYTOPENIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

CARCINOMA, SQUAMOUS CELL; EPIDERMOLYSIS BULLOSA; HUMANS; RISK FACTORS; SKIN NEOPLASMS;

EID: 0036458830     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2002.01130.x     Document Type: Review

References (35)

1. Fine JD, Eady RAJ, Bauer EA et al. Revised classification system for inherited epidermolysis bullosa: Report of the Second International Consensus Meeting on diagnosis and classification of epidermolysis bullosa. J Am Acad Dermatol 2000; 42: 1051-66.
2. Fine JD, Johnson LB et al. Cancer and inherited epidermolysis bullosa: Lifetable analyses of the national epidermolysis bullosa registry study population. In: Fine JD, Bauer EA, McGuire J, Moshell A eds. Epidermolysis Bullosa. Clinical, Epidemiologic and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry. Baltimore: The Johns Hopkins University Press, 1999: 175-92.
3. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: Incidence. J Am Acad Dermatol 1994; 30: 774-8.
4. Monk BE, Pembroke AC. Epidermolysis bullosa with squamous cell carcinoma. Clin Exp Dermatol 1987; 12: 373-4.
5. Swensson O, Christophers E. Generalized atrophic benign epidermolysis bullosa in 2 siblings complicated by multiple squamous cell carcinomas. Arch Dermatol 1998; 134: 199-203.
6. Parker SC, Schofield OMV, Black MM, et al. Non-lethal junctional epidermolysis bullosa complicated by squamous cell carcinoma. In: Priestley GC, Tidman MJ, Weiss JB, Eady RAJ, eds. Epidermolysis Bullosa: A Comprehensive Review of Classification Management and Laboratory Studies. Crowthorne: DEBRA, 1990: 103-6.
7. Weber F, Bauer JW, Sepp N et al. Squamous cell carcinoma in junctional and dystrophic epidermolysis bullosa. Acta Derm Venerol 2001; 81: 189-92.
8. Pellicano R, Fabrizi G, Cerimele D. Multiple keratoacan-thomas and junctional epidermolysis bullosa. A therapeutic conundrum. Arch Dermatol 1990; 126: 305-6.
9. Lear JT, Smith AG. Basal cell carcinoma. Postgrad Med J 1997; 73: 538-42.
10. Bauer JW, Schaeppi H, Kaserer C et al. Large melanocytic nevi in hereditary epidermolysis bullosa. J Am Acad Dermatol 2001; 44: 577-84.
11. Hoss DM, McNutt NS, Carter DM et al. Atypical melanocytic lesions in epidermolysis bullosa. J Cutan Pathol 1994; 21: 164-9.
12. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: Issues as we approach the 21st century. J Am Acad Dermatol 1996; 34: 839-47.
13. Martinez L, Goodman P, Crow WN. Squamous cell carcinoma of the maxillary sinus and plaque in epidermolysis bullosa: CT demonstration. J Comput Assist Tomogr 1992; 16: 317-9.
14. Yamauchi Y, Takahashi K, Shiotsu H. Osteogenic sarcoma of the tibia in a patient with epidermolysis bullosa dystrophica. Clin Orthop 1988; 228: 273-7.
15. Horn HM, Tidman MJ. The clinical spectrum of dystrophic epidermolysis bullosa. Br J Dermatol 2002; 146: 267-74.
16. McGrath JA, Schofield OMV, Mayou BJ et al. Epidermolysis bullosa complicated by squamous cell carcinoma: Report of 10 cases. J Cutan Pathol 1992; 19: 116-23.
17. Reed WB, College J, Francis MJO et al. Epidermolysis bullosa dystrophica with epidermal neoplasms. Arch Dermatol 1974; 110: 894-902.
18. Phillips TJ, Salman SM, Bhawan J, Rogers G. Burn scar carcinoma. Dermatol Surg 1998; 24: 561-5.
19. Dupree MT, Boyer JD, Cobb MW. Marjolin's ulcer arising in a burn scar. Cutis 1998; 62: 49-51.
20. Alconchel MD, Olivares C, Alvarez R. Squamous cell carcinoma, malignant melanoma and malignant fibrous histiocytoma arising in burn scars. Br J Dermatol 1997; 137: 793-8.
21. Dunnill MGS, Eady RAJ. The management of dystrophic epidermolysis bullosa. Clin Exp Dermatol 1995; 20: 179-88.
22. Slater SD, McGrath JA, Hobbs C et al. Expression of mutant p53 gene in squamous cell carcinoma arising in patients with recessive dystrophic epidermolysis bullosa. Histopathology 1992; 20: 237-41.
23. McGrath JA, Schofield OM, Mayou BJ et al. Metastatic squamous cell carcinoma resembling angiosarcoma complicating dystrophic epidermolysis bullosa. Dermatologica 1991; 182: 235-8.
24. Tabas M. Squamous cell carcinoma and dystrophic epidermolysis bullosa. In: Priestley GC, Tidman MJ, Weiss JB, Eady RAJ, eds. Epidermolysis Bullosa: A Comprehensive Review of Classification Management and Laboratory Studies. Crowthorne: DEBRA, 1990: 161.
25. Bastin KT, Steeves RA, Richards MJ. Radiation therapy for squamous cell carcinoma in dystrophic epidermolysis bullosa: Case reports and literature review. Am J Clin Oncol 1997; 20: 55-8.
26. Lentz SR, Raish RJ, Orlowski EP et al. Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy. Cancer 1990; 66: 1276-8.
27. Wechsler HL, Krugh FJ, Domonkos AN et al. Polydysplastic epidermolysis bullosa and the development of epidermal neoplasms. Arch Dermatol 1970; 102: 374-80.
28. Goldberg GI, Eisen AZ, Bauer EA. Tissue stress and tumor promotion. Possible relevance to epidermolysis bullosa. Arch Dermatol 1988; 124: 737-41.
29. Smoller BA, McNutt NS, Carter DM et al. Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated immunophenotype. Implications for carcinogenesis. Arch Dermatol 1990; 126: 78-83.
30. Arbiser JL, Fine JD, Murrell D et al. Basic fibroblast growth factor: A missing link between collagen VII, increased collagenase and squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. Mol Med 1998; 4: 191-5.
31. Tyring SK, Chopra V, Johnson L, Fine JD. Natural killer cell activity is reduced in patients with severe forms of inherited epidermolysis bullosa. Arch Dermatol 1989; 125: 797-800.
32. Chopra V, Tyring SK, Johnson L, Fine JD. Patients with severe forms of inherited epidermolysis bullosa exhibit decreased lymphokine and monokine production. J Clin Immunol 1990; 10: 321-9.
33. Lee SH, Shin MS, Kim HS et al. Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar. J Invest Dermatol 2000; 114: 122-6.
34. Leithäuser F, Dhein J, Mechtersheimer G et al. Constitutive and induced expression of APO-1, a new member of the new growth factor/tumour necrosis factor receptor superfamily, in normal and neoplastic cells. Laboratory Invest 1993; 69: 415-29.
35. Shimizu T, Izumi H, Oga A et al. Epidermal growth factor receptor overexpression and genetic aberrations in meta-static squamous-cell carcinoma of the skin. Dermatology 2001; 202: 203-6.